Lenalidomide, rituximab (R <sup>2</sup> ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma

Published:2024-03-08 Issue:6 Volume:65 Page:768-773
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Hill Brian T.¹^ORCID,Chen Yanwen²^ORCID,Jagadeesh Deepa¹^ORCID,Dean Robert¹^ORCID,Koc Omer¹,Boughan Kirsten³,Cooper Brenda³^ORCID,Pohlman Brad¹,Caimi Paolo¹^ORCID,Smith Mitchell R.¹⁴^ORCID

Affiliation:

1. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

2. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA

3. Case Western Reserve University School of Medicine, University Hospitals, Cleveland, OH, USA

4. The Follicular Lymphoma Foundation, Washington, DC, USA

Funder

Celgene; Takeda Pharmaceutical Company

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2325636

Reference15 articles.

1. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

2. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era

3. Follicular Lymphoma International Prognostic Index

4. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

5. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project